

**PRUCALOPRIDE SUCCINATE 1mg TABLETS**

ACCORDING TO EC-REGULATIONS 1907/2006 (REACH), 1272/2008 (CLP) &amp; 2020/878

**SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING****1.1 Product Identifier**

Product Name PRUCALOPRIDE SUCCINATE 1mg TABLETS

Mixture  
Contains PRUCALOPRIDE drug substance

**1.2 Relevant identified uses of the substance or mixture and uses advised against**

Identified Use Medicinal product  
Uses advised against Other uses different from identified.

**1.3 Details of the supplier of the Safety Data Sheet**

Manufacturer  
Company Identification Combino Pharm (Malta) Ltd.  
Address of Manufacturer 60 Qasam Industriali Hal Far  
BBG3000, Hal Far, Birzebbugia  
Malta

**E-mail****1.4 Emergency telephone number****Emergency Phone No.****SECTION 2: HAZARDS IDENTIFICATION****2.1 Classification of the substance or mixture**

Regulation (EC) No. 1272/2008 (CLP) Not classified.

**2.2 Label elements**

Product Name According to Regulation (EC) No. 1272/2008 (CLP)  
PRUCALOPRIDE Tartrate 1 mg tablets

Hazard Pictogram(s) Not classified.

Signal Word(s) Not classified

Hazard Statement(s) Not classified.

Precautionary Statement(s) Not classified.

**2.3 Other hazards** This material contains an active pharmaceutical ingredient, PRUCALOPRIDE.**SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS****3.1. Substances**

Not applicable.

**3.2. Mixture**

HAZARDOUS INGREDIENT(S)	CAS No.	EINECS No.	%(w/w)	Hazard Statement(s)	Hazard Pictogram(s)
PRUCALOPRIDE SUCCINATE	179474-85-2	680-639-5	*	H302	GHS07

\*Proprietary data

The materials included in this section are those hazardous substances present in the composition.  
The total composition and materials included in the mixture is confidential and proprietary information.

**SECTION 4: FIRST AID MEASURES****4.1 Description of first aid measures**

Inhalation Remove person to fresh air and keep comfortable for breathing.

**PRUCALOPRIDE SUCCINATE 1mg TABLETS**

Skin Contact	If exposed or concerned: Get medical advice/attention.
Eye Contact	Call a poison center or a doctor if you feel unwell. Wash skin with plenty of water.
Ingestion	Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTRE/doctor. Do not give an unconscious person anything to drink. Rinse mouth. Call a poison center or a doctor if you feel unwell.

**4.2 Most important symptoms and effects, both acute and delayed**

See section 11.

**4.3 Indication of any immediate medical attention and special treatment needed**

Treat symptomatically.

**SECTION 5: FIREFIGHTING MEASURES****5.1 Extinguishing media**

Suitable Extinguishing media	Water spray. Dry powder. Foam.
Unsuitable extinguishing media	None identified.

**5.2 Special hazards arising from the substance or mixture**

May decompose in a fire, giving off toxic and irritant vapours.

**5.3 Advice for firefighters**

Fire fighters should wear complete protective clothing including self-contained breathing apparatus. Dike fire control water for later disposal.

**SECTION 6: ACCIDENTAL RELEASE MEASURES****6.1 Personal precautions, protective equipment and emergency procedures**Provide adequate ventilation. Minimize potential for exposure.  
Do not attempt to take action without suitable protective equipment. For further information refer to section 8: "Exposure controls/personal protection".**6.2 Environmental precautions**Avoid release to the environment.  
Spillages or uncontrolled discharges into watercourses must be alerted to the appropriate regulatory body.**6.3 Methods and material for containment and cleaning up**Mechanically recover the product.  
Notify authorities if product enters sewers or public waters.**6.4 Reference to other sections**

See also sections 8, 13.

**SECTION 7: HANDLING AND STORAGE****7.1 Precautions for safe handling**

Ensure good ventilation of the work station. Avoid dust formation. If tablets are crushed and/or broken, avoid breathing dust and avoid contact with skin, eyes, or clothing. Do not eat, drink, or smoke during use. Wash hands and potentially exposure skin immediately after handling the product. Wash contaminated clothes. Do not handle until all safety precautions have been read and understood. Wear personal protective equipment.

**7.2 Conditions for safe storage, including any incompatibilities**

Storage conditions	Keep container tightly closed. Store in the original container to protect from moisture. Store at 20°C to 25°C; excursions permitted between 15°C to 30°C [see USP controlled room temperature].
Storage life	Stable under normal conditions.
Incompatible materials	None known.

**7.3 Specific end use(s)**

Medicinal product.

## PRUCALOPRIDE SUCCINATE 1mg TABLETS

### SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

#### 8.1 Control parameters

8.1.1. Internal Occupational Exposure Band: OEB-3B (1-10 µg/m<sup>3</sup>) [internal value] (prucalopride succinate)

#### 8.2 Exposure controls

8.2.1. Appropriate engineering controls Ensure adequate ventilation. A washing facility/water for eye and skin cleaning purposes should be present. Prioritize technical measures and work methods appropriate to the use of individual protection equipment.

8.2.2. Personal protection equipment Adapt the most appropriate Personal Protection Equipment (PPE) according to the risk assessment carried out by the company in the workplace and in the working conditions. In those scenarios where the collective and general protections applied are not sufficient, PPE must be used in accordance with the indications of current regulations.



Eye Protection

Safety glasses in accordance with the EN 166 standard if potential for eye contact is identified.



Skin Protection

Recommended nitrile glove, 0.11mm, penetration time >480 minutes.  
Recommended body protective clothing if there is a risk of exposure or contact.  
Personal protective equipment for skin protection should meet current standards.



Respiratory protection

Use respiratory protective equipment according to the risk of exposure and the Occupational Exposure limits established.



Thermal hazards

None known.

8.2.3. Environmental Exposure Controls Spillages or uncontrolled discharges into watercourses must be alerted to the appropriate regulatory body.

### SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

#### 9.1 Information on basic physical and chemical properties

Physical state	Tablet.
Colour	White to off-white.
Odour	Odourless
Melting point/freezing point	Not known.
Boiling point or initial boiling point and boiling range	Not known.
Flammability	Not known.
Lower and upper explosion limit	Not known.
Flash Point	Not known.
Auto-ignition temperature	Not known.
Decomposition Temperature	Not known.
pH	Not known.
Kinematic Viscosity	Not known.
Solubility	Not known.
Partition coefficient n-octanol/water (log value)	Not known.
Vapour pressure	Not known.
Density and/or relative density	Not known.
Relative vapour density	Not known.
Particle characteristics	Not known.

**PRUCALOPRIDE SUCCINATE 1mg TABLETS****9.2 Other information**

Not known.

**SECTION 10: STABILITY AND REACTIVITY****10.1 Reactivity**

None anticipated.

**10.2 Chemical Stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

No hazardous reactions known if used for its intended purpose.

**10.4 Conditions to avoid**Keep away from heat and direct sunlight. Avoid ignition sources.  
Store in the original container to protect from moisture.**10.5 Incompatible materials**

Keep away from oxidizers, strong acids and strong bases.

**10.6 Hazardous decomposition products**

No hazardous decomposition products known.

**SECTION 11: TOXICOLOGICAL INFORMATION****11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008**

## Acute toxicity - Ingestion

Harmful if swallowed.

LD50 Oral (rat): &gt; 640 mg/kg (data for prucalopride succinate drug substance)

## Acute toxicity - Skin Contact

Not classified. No data available.

## Acute toxicity - Inhalation

Not classified. No data available.

## Skin corrosion/irritation

Not classified. No data available.

## Serious eye damage/irritation

Not classified. No data available.

## Skin sensitization data

Not classified. No data available.

## Respiratory sensitization data

Not classified. No data available.

## Germ cell mutagenicity

The weight of evidence from *in vitro* and *in vivo* assays showed no genotoxicity concern for prucalopride.

## Carcinogenicity

There is no evidence that this product represents a carcinogenic risk under normal conditions of handling and use.

## Reproductive toxicity

Not classified.

## Lactation

Not classified.

## STOT - single exposure

Not classified.

## STOT - repeated exposure

Not classified.

## Aspiration hazard

Not classified

**11.2 Information on other hazards**

Unknown.

**SECTION 12: ECOLOGICAL INFORMATION****12.1 Toxicity**

Not known.

**12.2 Persistence and degradability**

Not known.

## PRUCALOPRIDE SUCCINATE 1mg TABLETS

<b>12.3 Bioaccumulative potential</b>	Not known.
<b>12.4 Mobility in soil</b>	Not known.
<b>12.5 Results of PBT and vPvB assessment</b>	Not known.
<b>12.6 Endocrine disrupting properties</b>	Not known.
<b>12.7 Other adverse effects</b>	Not known.

### SECTION 13: DISPOSAL CONSIDERATIONS

<b>13.1 Waste treatment methods</b>	Dispose of contents in accordance with local, state or national legislation. Send to a licensed recycler, reclaimer or incinerator. Dispose of this material and its container to hazardous or special waste collection point. Dispose at suitable refuse site.
<b>13.2 Additional Information</b>	Disposal should be in accordance with local, state or national legislation.

### SECTION 14: TRANSPORT INFORMATION

This material is not regulated as dangerous for transport.

<b>14.1 UN number or ID number</b>	
UN No.	Not regulated
<b>14.2 UN proper shipping name</b>	
UN proper shipping name	Not regulated
<b>14.3 Transport hazard class(es)</b>	
ADR/RID	
ADR/RID Class	Not regulated
IMDG	
IMDG Class	Not regulated
ICAO/IATA	
Labels	Not regulated
<b>14.4 Packing group</b>	
Packing group	Not regulated
<b>14.5 Environmental hazards</b>	
Environmental hazards	Not regulated
<b>14.6 Special precautions for user</b>	
Special precautions for user	Not known.
<b>14.7 Maritime transport in bulk according to IMO instruments</b>	
	No information available

### SECTION 15: REGULATORY INFORMATION

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

European Regulations - Authorisations and/or Restrictions On Use

Candidate List of Substances of Very High Concern for Authorisation	Not listed
REACH: ANNEX XIV list of substances subject to authorisation	Not listed
REACH: Annex XVII Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	Not listed
Community Rolling Action Plan (CoRAP)	Not listed
Regulation (EU) N° 2019/1021 of the European Parliament and of the Council on persistent organic pollutants	Not listed
Regulation (EC) N° 1005/2009 on substances that deplete the ozone layer	Not listed
Regulation (EU) N° 649/2012 of the European Parliament and of the Council concerning the export and import of hazardous chemicals	Not listed

**PRUCALOPRIDE SUCCINATE 1mg TABLETS****National regulations**

Other

Not known.

**15.2 Chemical Safety Assessment**

A REACH chemical safety assessment has not been carried out.

**SECTION 16: OTHER INFORMATION**

The following sections contain revisions or new statements:

None. New document (version 1.0).

**LEGEND**

Hazard Statement(s)

H302 – Harmful if swallowed.

Key literature references and sources for data used to compile the SDS

Regulation (EC) No. 1272/2008 (CLP)  
Preparation of Safety Data Sheets for Hazardous Chemicals Code of Practice. Safe Work Australia. Updated June 2023.

Disclaimers

ALL INFORMATION CONTAINED HEREIN IS PROVIDED FOR GUIDANCE ONLY AND IS OFFERED IN GOOD FAITH AND UNDER THE BELIEF THAT IT IS ACCURATE. THE INFORMATION IN THIS MATERIAL SAFETY DATA SHEET REFERS TO THE ABOVE PRODUCT, BUT MAY NOT BE VALID FOR COMBINATION WITH OTHER PRODUCTS OR ANY OTHER PROCESSES. COMBINOPHARM MAKES NO WARRANTY OF MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE, OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, REGARDING THE ACCURACY OR COMPLETENESS OF THIS INFORMATION, THE SAFETY OF THIS PRODUCT, OR THE HAZARDS RELATED TO ITS USE. USERS SHOULD MAKE THEIR OWN INVESTIGATIONS TO DETERMINE THE SUITABILITY OF THE INFORMATION OR PRODUCT FOR THEIR PARTICULAR PURPOSES AND ON THE CONDITION THAT BECAUSE OF THE NATURE OF THE PRODUCT, THEY ASSUME ALL RISK WITH RESPECT TO IT. IN NO EVENT COMBINOPHARM SHALL BE LIABLE FOR ANY CLAIMS, LOSSES, OR DAMAGES OR ANY THIRD PARTY OR FOR LOST PROFITS OR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING FROM THE USE OF THIS INFORMATION OR THE PRODUCT.